AstraZeneca prices bond to fund Alexion acquisition with 0.375% coupon

(Alliance News) - AstraZeneca PLC on Thursday said it has priced its issue of EUR800 million in ...

Alliance News 27 May, 2021 | 9:00AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Thursday said it has priced its issue of EUR800 million in bonds maturing in 2029 with a coupon of 0.375% to help fund its acquisition of Alexion Pharmaceuticals Inc.

The bonds mature on June 3, 2029. The bonds are among those that will be redeemed if the deal to acquire Alexion is not completed by March 2022, AstraZeneca said.

The Cambridge-based pharmaceutical firm is buying Boston, US-based biotech Alexion in a deal worth USD39 billion, with the deal announced back in December. On Tuesday, however, the UK's Competition & Markets Authority said it was investigating the takeover.

The euro-denominated bonds are part of an overall USD7.0 billion bond offer that was announced on Wednesday to fund the purchase of Alexion.

AstraZeneca shares down at 0.1% at 8,012.00 pence each in London on Thursday morning.

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 8,480.00 GBX 0.25
Alexion Pharmaceuticals Inc

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement